Brolucizumab for wet age-related macular degeneration
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Brolucizumab is a monoclonal antibody specific for vascular endothelial growth factor (VEGF). It is indicated for treatment of wet age-related macular degeneration (AMD), and is administered as an intravitreal injection every eight or 12 weeks.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation